# Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis

> **NCT00141830** · PHASE2 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 159 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Methotrexate plus ERB-041 for 12 weeks
- **DRUG:** Placebo for 12 weeks

## Key facts

- **NCT ID:** NCT00141830
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2006-10-19
- **Final completion:** 2006-10-19
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2020-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00141830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00141830, "Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00141830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*